Finally, the combined treatment of Tankyrase inhibitors with other drugs, including novel targeted therapy drugs or immunotherapy drugs, should be explored in detail in vitro and in vivo for HCC treatment. This evidence concerns the gene TNKS and hepatocellular carcinoma.